Abstract
Failure to perform the Fas-related apoptosis pathway can account for tumor resistance both to chemotherapeutic agents and to immunological effectors. We studied the role of NK-kappaB in Fas-resistance, employing the Fas-sensitive human T-lymphoma HuT78 cell line and its Fas-resistant variants HuT78B1 and HuT78G9. All these cell lines expressed high levels of constitutively activated NF-kappaB. Pretreatment of cells with NF-kappaB inhibitors (PDTC, MG132, or SN50) strongly enhanced CH11-induced apoptosis in HuT78 and Hut78G9 cells, while only MG132 showed a similar potentiating effect in HuT78B1. The described synergism was significantly inhibited by pretreatment with the anti-Fas-blocking antibody ZB4 or with the pancapsase inhibitor Z-VAD-FMK, but not by capsase-8 or -9 inhibitors. Overall, these data suggest that NF-kappaB inhibition may restore the Fas-pathway in Fas-resistant NF-kappaB-overexpressing tumors.
Lingua originale | English |
---|---|
pagine (da-a) | 232-236 |
Numero di pagine | 5 |
Rivista | Annals of the New York Academy of Sciences |
Volume | 1010 |
Stato di pubblicazione | Published - 2003 |
All Science Journal Classification (ASJC) codes
- ???subjectarea.asjc.2800.2800???
- ???subjectarea.asjc.1300.1300???
- ???subjectarea.asjc.1200.1207???